Theralase Technologies Inc. V.TLT

17B$ = BCG market as standard treatment of care

[ScienceFirst]

This is what is compelling to big pharma; the possibility to also displace BCG in early-stage setting of NMIBC, now that we have demonstrated high CR % @90-days and long duration DR %.  Not just in BCG-Unresponsive.

That would represent a market opportunity of 17B$US/year.  That's 170,000 patients treated each year with BCG as standard treatment of care (as per p. 6 of TLT's presentation) x 100,000$US/treatment.

You bet that a big pharma would do everything to advance TLD1433 in the early-stage setting and displace BCG as the SOC (standard of care).

Again, we have high efficacy %s.  And no need to have 16+ treatments.

Compelling to patients.  Amazing business opportunity for a big pharma to reap major market shares.

We get Accelerated Approval and a jv follows.


https://theralase.com/wp-content/uploads/2022/07/Presentation-2022.pdf

[99942Apophis]

Excellent information ScienceFirst although looking at 17 billion US dollars is representative of world markets. Theralase currently would be able if granted AA to earn revenue in Canada & US and their combined total is half of the projected figure of 170,000 to be 85,000 in the upcoming year. I must admit once Theralase's success in this Ph2 study trial is broadcast throughout the medical

[ScienceFirst]

99992Apophis ... HC approval gives instant access to 70 countries.  FDA approval to even more.  Many countries rely on regulatory bodies like HC, FDA, EU (CE) bodies to allow drugs to be accepted in their countries as they don't have to knowledge to challenge. There's also this quite new recent program (2018) called Project Orbis that allows concurrent submission of oncology

[99942Apophis]

Very exciting and thank you for that speedy response. That will open my window to larger mathematical revenue in my next "rough" calculation of possible future values.  

[BlueFranky]

Apophis - I for one eagerly await your next calculations!

[ScienceFirst]

The BCG market is worth 17B$US, as per the TLT corporate presentation. _______________   ScienceFirst - (12/15/2022 8:54:34 PM) 17B$ = BCG market as standard treatment of care This is what is compelling to big pharma; the possibility to also displace BCG in early-stage setting of NMIBC, now that we have demonstrated high CR % @90-days and long duration DR %.  Not